Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Recommendation of “Moderate Buy” from Analysts

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has received a consensus rating of “Moderate Buy” from the eight analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $9.5833.

A number of equities analysts have issued reports on XERS shares. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a report on Friday, November 7th. Piper Sandler boosted their target price on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday, October 8th. Zacks Research downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 30th. Finally, Leerink Partners upped their price objective on shares of Xeris Biopharma from $7.00 to $9.00 and gave the company an “outperform” rating in a report on Tuesday, August 19th.

Xeris Biopharma Price Performance

Shares of NASDAQ:XERS opened at $7.04 on Tuesday. Xeris Biopharma has a 1 year low of $3.05 and a 1 year high of $10.08. The business’s 50-day moving average is $8.28 and its 200-day moving average is $6.61. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -70.39 and a beta of 0.21.

Insider Transactions at Xeris Biopharma

In other news, Director Jeffrey W. Sherman sold 42,232 shares of the business’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $7.92, for a total transaction of $334,477.44. Following the completion of the sale, the director owned 219,188 shares in the company, valued at $1,735,968.96. The trade was a 16.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider John Patrick Shannon, Jr. sold 23,242 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $7.46, for a total value of $173,385.32. Following the transaction, the insider directly owned 2,643,153 shares in the company, valued at $19,717,921.38. The trade was a 0.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 97,641 shares of company stock valued at $750,859. 4.56% of the stock is currently owned by corporate insiders.

Institutional Trading of Xeris Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of XERS. AlphaQuest LLC acquired a new position in Xeris Biopharma during the third quarter worth $35,000. FORA Capital LLC bought a new stake in shares of Xeris Biopharma during the first quarter worth about $60,000. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after acquiring an additional 5,000 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of Xeris Biopharma in the 3rd quarter worth about $68,000. Finally, Tower Research Capital LLC TRC lifted its position in Xeris Biopharma by 913.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,395 shares of the company’s stock valued at $81,000 after acquiring an additional 15,678 shares in the last quarter. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.